Why is SMS Pharma. falling/rising?

Strong Price Momentum and Market Outperformance

SMS Pharmaceuticals has demonstrated remarkable price momentum in recent trading sessions. The stock has gained 13.99% over the past week, vastly outperforming the Sensex’s modest 0.50% rise during the same period. Over the last month, SMS Pharma. has appreciated by 8.13%, compared to the Sensex’s 1.66%, while year-to-date returns stand at an impressive 34.50%, significantly ahead of the benchmark’s 9.56%. This trend extends over longer horizons, with the stock delivering 21.80% returns in the last year against the Sensex’s 7.01%, and an extraordinary 281.10% gain over three years, dwarfing the benchmark’s 37.43%.

On 26-Nov, the stock traded close to its 52-week high, just 1.98% shy of the peak price of ₹329. It touched an intraday high of ₹327, reflecting a 19.34% increase on the day. The stock’s performance also outpaced its sector by 16.59%, underscoring its relative strength within the pharmaceutical industry. Notably, SMS Pharma. has been on a consecutive two-day winning streak, accumulating an 18.69% return in this short span.

Technical Indicators and Trading Activity

From a technical perspective, SMS Pharmaceuticals is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend. The stock has experienced a wide trading range of ₹47.95 during the day, indicating heightened volatility and active price discovery. However, despite the price surge, investor participation appears to have moderated, with delivery volumes on 25 Nov falling by 45.38% compared to the five-day average. This suggests that while the stock is rising sharply, the volume of shares actually changing hands on a delivery basis has declined, a factor investors may wish to monitor for sustainability of the rally.

Fundamental Strength Underpinning the Rally

The recent price appreciation is supported by solid fundamental performance. SMS Pharmaceuticals reported net sales of ₹438.48 crores for the latest six-month period, reflecting a healthy growth rate of 21.40%. This robust sales expansion is complemented by an impressive return on capital employed (ROCE) of 12.36% for the half-year, indicating efficient utilisation of capital to generate profits. Additionally, the company maintains a conservative debt-equity ratio of 0.45 times, suggesting a manageable level of leverage and financial stability.

These fundamentals have translated into consistent returns for investors. Over the past three years, SMS Pharma. has outperformed the BSE500 index in each annual period, reinforcing its status as a strong performer within the small-cap pharmaceutical space. The stock’s ability to generate 21.80% returns in the last year alone, well above the broader market’s 7.01%, highlights its resilience and growth potential.

Balancing Momentum with Liquidity and Participation

While the stock’s liquidity is sufficient for moderate trade sizes, with a trading capacity of approximately ₹0.06 crores based on 2% of the five-day average traded value, the decline in delivery volume may warrant caution. The weighted average price indicates that more volume was traded closer to the day’s low price, which could imply some profit-taking or cautious positioning by traders despite the overall upward trajectory.

In summary, SMS Pharmaceuticals’ sharp rise on 26-Nov is primarily driven by strong sales growth, solid profitability metrics, and sustained outperformance relative to market benchmarks. The technical strength and proximity to 52-week highs further bolster investor confidence. However, the dip in delivery volumes suggests that market participants should watch for confirmation of sustained buying interest to support further gains.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →